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Alzheimer3s diseaseResting state functional MRI (rs-fMRI) has been previously shown to be a promising tool for the assessment of
early Parkinson3s disease (PD). In order to assess whether changes within the basal ganglia network (BGN) are
disease speciﬁc or relate to neurodegeneration generally, BGN connectivity was assessed in 32 patients with
early PD, 19 healthy controls and 31 patients with Alzheimer3s disease (AD). Voxel-wise comparisons demon-
strated decreased connectivity within the basal ganglia of patients with PD, when compared to patients with
AD andhealthy controls. No signiﬁcant changeswithin the BGNwere seen inAD,when compared to healthy con-
trols. Moreover, measures of functional connectivity extracted from regions within the basal ganglia were signif-
icantly lower in the PD group. Consistent with previous radiotracer studies, the greatest change when compared
to thehealthy control groupwas seen in the posterior putamenof PD subjects.When combined into a single com-
ponent score, this method differentiated PD from AD and healthy control subjects, with a diagnostic accuracy of
81%. Rs-fMRI can be used to demonstrate the aberrant functional connectivitywithin the basal ganglia of patients
with early PD. These changes are likely to be representative of patho-physiological basal ganglia dysfunction and
are not associated with generalised neurodegeneration seen in AD. Further studies are necessary to ascertain
whether this method is sensitive enough to detect basal ganglia dysfunction in prodromal PD, and its utility as
a potential diagnostic biomarker for premotor and early motoric disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson3s disease (PD) is a progressive, neurodegenerative disor-
der characterised by the cardinal motor symptoms of resting tremor, ri-
gidity, bradykinesia and postural instability (Jankovic, 2008). At the
time these symptoms ﬁrst emerge, and the clinical diagnosis of PD can
be made, approximately 70% of the dopaminergic neurons within the
ventro-lateral tier of the substantia nigra pars compacta have been irre-
versibly lost (Fearnley and Lees, 1991). It has been suggested that the
loss of these neurons may begin 5–10 years prior to the onset of ﬁrst
motor symptoms (Fearnley and Lees, 1991). Intervention during this
stage of the disease is likely to have the biggest impact on the natural
history of the disease, slowing progression or even preventing the
onset of the cardinal symptoms.niversity of Oxford, Warneford
fax: +44 (0)1865 793101.
ckay).
. This is an open access article underWhilst this prodromal stage of the disease is characterised by a
plethora of non-motor symptoms, such as depression and anxiety
(Shiba et al., 2000), constipation (Abbott et al., 2001) and hyposmia
(Ross et al., 2008), and associated motor symptoms, such as REM
sleep behaviour (Schenck et al., 2013), most of these lack the speciﬁcity
necessary to diagnose early disease. Therefore, there is a critical need for
biomarkers in PD to enable diagnosis in the prodromal phase and iden-
tify individuals who may beneﬁt from future targeted therapies. Objec-
tive biomarkers are also necessary to monitor disease progression and
demonstrate treatment efﬁcacy.
Resting state functional fMRI (rs-fMRI) has shown promise as a
potential biomarker in a number of neurodegenerative conditions
(Balthazar et al., 2014; Dopper et al., 2014; Wolf et al., 2014). Over the
past few years, the identiﬁcation of the resting state basal ganglia net-
work (BGN) (Laird et al., 2011; Luo et al., 2012; Robinson et al., 2009)
has opened the door to investigating PD using this technique. In a
study recently published by our group (Szewczyk-Krolikowski et al.,
2014a), we have shown that changes within the BGN can differentiatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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drawal) from healthy controls, and conﬁrmed near-normalisation of
the network with levodopa treatment. However, the use of a data-
drivenmethod to study thewhole of the BGN potentially opens this ap-
proach to interference from non-PD-speciﬁc group differences that may
have an impact on the overall accuracy of the method when replicated
using greater sample sizes. Moreover, it is not clear whether these
changes are speciﬁc to PD or whether they are representative of a
more global process.
Basal ganglia dysfunction invariably lies at the heart of Parkinson3s
disease (Eidelberg et al., 1990). Therefore, we set out to test whether a
priori conﬁnesmay be placed upon the analysis to establish a functional
imaging signature for PD that is separate from the ageing process as a
whole, as well as other forms of neurodegeneration known to have an
impact on resting state networks (Pievani et al., 2014). We have used
a resting state functionalMRI (rs-fMRI) protocol to investigate the func-
tional changes conﬁned to the caudate, pallidum and putamen of pa-
tients with PD. To assess whether any changes are disease speciﬁc or
may also relate to other forms of neurodegeneration, BGN connectivity
in PD patients was compared to both healthy controls and patients with
Alzheimer3s disease, an example of a neurodegenerative disease with
predominantly cortical neurodegeneration but also subcortical involve-
ment (Ikonomovic et al., 2008). The methodology represents a reﬁne-
ment of our previous analysis (Szewczyk-Krolikowski et al., 2014a),
towards development of a potential diagnostic biomarker.2. Methods
2.1. Participants
Thirty-twopatientswith early PD (within 3.5 years of diagnosis) and
19 healthy-controls were recruited from the Oxford Parkinson3s Disease
Centre (OPDC) cohort (Rolinski et al., 2014). These participants were
the same as those in our previous study (Szewczyk-Krolikowski et al.,
2014a). Prior to recruitment into the imaging arm of the study, all par-
ticipants underwent extensive assessment, including a structured gen-
eral medical interview, detailed characterisation of motor and non-
motor features, and cognitive assessment. Full description of the assess-
ment is available elsewhere (Szewczyk-Krolikowski et al., 2014a;
Szewczyk-Krolikowski et al., 2014b). Only patients that met the UK PD
Society Brain Bank Criteria for clinically probable idiopathic Parkinson3s
disease (Hughes et al., 1992), as assessed by the study neurologist, were
included in the PD group. Moreover, in order to select a clinically ho-
mogenous group and minimise the effect of movement artefact, only
the participants with minimal tremor were selected. PD subjects were
scanned in a clinically deﬁned “off-state”, a minimum of 12 h after the
withdrawal of their dopaminergic medications. Twenty-eight of the pa-
tients were also scanned in the “on-state” 60–90 min after taking their
own dopaminergic medication. The patients scanned in the clinically
deﬁned “off-state” will herein be referred to as the PD group. The
healthy control group consisted of subjects with no family history of
parkinsonism, recruited largely from the spouses and friends of the PD
participants. Healthy controls were not receiving any medications
known to affect the dopaminergic system. Both groups only included
subjects classiﬁed as cognitively healthy, as deﬁned by a Mini-Mental
State Examination (MMSE) N26 and no subjective complaint ofmemory
problems.
A further thirty-one patients with clinically probable Alzheimer3s
disease were recruited from the Oxford Project to Investigate Memory
and Ageing and from the Memory Assessment Clinic at the John Rad-
cliffe Hospital in Oxford, United Kingdom (Zamboni et al., 2013). Pa-
tients with AD met both the DSM-IV for dementia and the National
Institute of Neurological and Communicative Disease and Stroke/
Alzheimer3s Disease and Related Disorders Association criteria for prob-
able AD dementia and had never taken cholinesterase inhibitors.The study was undertaken with the understanding and written con-
sent of each subject, with the approval of the local NHS ethics commit-
tee, and in compliance with national legislation and the Declaration of
Helsinki.2.2. Neuroimaging data acquisition
Scanning was performed at the Oxford Centre for Clinical Magnetic
Resonance Research (OCMR) using a 3 T Trio Siemens MRI scanner (Er-
langen, Germany) equipped with a 12-channel head coil.
For each subject, T1-weighted images were obtained using a 3D
Magnetisation Prepared-Rapid Acquisition Gradient Echo (MP-RAGE)
sequence (192 axial slices, ﬂip angle 8°, 1 × 1 × 1 mm3 voxel size, TE/
TR/TI = 4.7 ms/2040 ms/900 ms). Acquisition time for the MP-RAGE
was 6 min.
Functional images were acquired using gradient echo planar imag-
ing (EPI) (TR = 2000 ms, TE = 28 ms, ﬂip angle = 89°, resolution =
3× 3 × 3.5mm). Thirty-four axial slices were acquired per volume, cov-
ering both hemispheres with incomplete coverage of the cerebellum;
180 repetitions were acquired in 6 min. Participants were instructed
to remain still and awake with their eyes open.
Field maps were also acquired to reduce EPI distortion due to mag-
netic ﬁeld inhomogeneity (TR = 488 ms, TE = 5.19 and 7.65 ms).2.3. Brain volume measurements
Brain tissue volume, normalised for subject head size, was estimated
with SIENAX (Smith et al., 2002). Tissue-type segmentationwith partial
volume estimationwas carried out (Zhang et al., 2001) in order to calcu-
late grey matter volumes. Volumes of the subcortical structures were
estimated using FMRIB3s Integrated Registration and Segmentation
Tool (FIRST) (Patenaude et al., 2011). The volume of each subcortical
structure was adjusted for individual head size differences via multipli-
cation by the volumetric scaling factor derived from SIENAX.2.4. Analysis of resting-state functional magnetic resonance imaging
Resting state analysis was performed using probabilistic indepen-
dent component analysis (ICA) as implemented in the Multivariate
Exploratory Linear Optimised Decomposition into Independent Compo-
nent FSL tool (MELODIC) (Beckmann and Smith, 2004), part of the FSL
software package (Woolrich et al., 2009). Individual pre-statistical pro-
cessing consisted of motion correction, brain extraction, unwarping
using ﬁeldmap data, spatial smoothing using Gaussian kernel of
FWHM of 6 mm, and high-pass temporal ﬁltering of 150 s. To account
for the effect of motion, non-neural physiology, scanner artefacts and
other confounds, we employed a previously described ICA-based de-
noising approach. Brieﬂy, after performing subject-level ICA with auto-
mated dimensionality estimation, the FIX tool was used to automatical-
ly classify the obtained components into signal or noise (Salimi-
Khorshidi et al., 2014). The contribution of noise was then regressed
out from the data, based on the unique variance related to the noise
components and motion confounds from the preprocessed data sets
(Griffanti et al., 2014).
Once preprocessed, data were linearly registered to the correspond-
ing structural image using FLIRT (Jenkinson et al., 2002), optimised
using Boundary-Based Registration, and registered to Montreal Neuro-
logical Institute (MNI) space using non-linear registration.
In order to allow direct comparison across the three cohorts, a rest-
ing state template, including the basal ganglia network (BGN) and 21
residual noise components, generated from 80 healthy elderly subjects
was used (Szewczyk-Krolikowski et al., 2014a) (Fig. 1). The 21 residual
noise components that were included were not fully removed by FIX
and were identiﬁed as residual noise based on the identiﬁcation of
Fig. 1. An unbiased template of the resting state basal ganglia network (BGN) generated
from 80 healthy controls (Szewczyk-Krolikowski et al., 2014a). The spatial map is
thresholded at z N 2.6.
128 M. Rolinski et al. / NeuroImage: Clinical 8 (2015) 126–132standard noise components (Beckmann, 2012) and location of signal
peaks in non-grey matter areas (e.g. white matter, CSF, skull).
The dual regression approach (Filippini, 2009) was used to identify
individual temporal dynamics and the associated spatial maps of the
BGN. In the ﬁrst step of dual regression, the template including the
BGN and 21 noise components maps was used in a general linear
model (GLM) ﬁt (as spatial regressors) against the separate fMRI data
sets previously cleaned with FIX, the output being the corresponding
temporal dynamics for each component and subject. Secondly, these
time-courses were used in a second GLM ﬁt (as temporal regressors)
against the cleaned fMRI data sets to estimate subject-speciﬁc spatial
maps. Finally, the BGN maps were collected across subjects and tested
voxel-wise for statistically signiﬁcant differences between groups
using non-parametric permutation testing with randomise (v. 2.1).
The statistical analysis was conﬁned to the basal ganglia as deﬁned by
the Harvard-Oxford Subcortical Atlas (Mazziotta, 2001), in order to
test intra-basal ganglia functional connectivity. Results were corrected
for age, sex and total grey matter volume, and deﬁned as signiﬁcant at
p b 0.05 fully corrected for multiple comparisons using the Threshold-
Free Cluster Enhancement (TFCE) approach (Smith and Nichols, 2009).
2.5. Subcortical regions of interest
Subcortical masks were created from the Harvard-Oxford Subcorti-
cal Atlas (Mazziotta, 2001). The generated masks were used to extract
mean parameter estimates (P.E.), representing the connectivity of a
given voxels with the timecourse of the whole network, from subject-
speciﬁc BGN spatial maps, from the following ROIs: caudate, pallidumand the posterior and anterior putamen, bilaterally. The boundary be-
tween the anterior and posterior putamenwas taken to be the posterior
aspect of the fornix on the axial plane.
2.6. Statistical analysis
All statistical analyses in this study, other than the statistical analy-
ses included in the MRI analysis tools, were performed using Statistical
Package for the Social Sciences version 22.0 (SPSS, Chicago, IL, USA).
Demographic, clinical and volumetric MRI continuous data were statis-
tically compared between the groups using analysis of variance
(ANOVA); the Bonferronimethodwas used to correct formultiple com-
parisons. The Pearson χ2 test was to compare ordinal variables. A prin-
cipal component analysis (PCA)-based dimension reduction method
was used to combine values extracted from the ROIs of all subjects
into a single factor. The alpha was set at 0.05.
3. Results
3.1. Participants
Mean disease duration for patients with PD (n = 32) was 25.0
(13.9) months. There were no signiﬁcant differences in age, sex,
MMSE, total grey matter or subcortical volumes between healthy con-
trols and subjects with PD (Table 1). Subjects with AD were older and
had reduced whole-brain grey matter volume and the volume of the
putamen.
3.2. Resting state fMRI analysis
Details of mean absolute head motion and the proportion compo-
nents identiﬁed as noise by FIX are shown in Supplementary Table 1.
No subjects had to be excluded on the basis of excessive head motion.
On average, patients with AD hadmore headmotion, and had amargin-
ally larger proportion of components identiﬁed as noise, when com-
pared to subjects with PD but not healthy controls. The mean
connectivity maps for each group are shown in Supplementary Fig. 1.
3.2.2. Voxel-wise analysis
Voxel-wise comparisons restricted to the basal ganglia demonstrat-
ed widespread decrease in connectivity within the network in subjects
with PD when compared to healthy controls, subjects with AD, and
healthy controls and patients with AD, combined (Fig. 2). Reduced con-
nectivity was observed in the caudate, pallidum and the putamen, bilat-
erally. No differences within the basal ganglia network were found
between the HC and AD groups.
3.2.3. Region of interest analysis
As demonstrated in the voxel-wise analysis, measures of functional
connectivity within the regions of interest were markedly altered in
the Parkinson3s disease group (Table 2 and Fig. 3). Mean parameter es-
timates (P.E.) were signiﬁcantly lower in all of the subcortical regions,
with the greatest decrease in P.E., compared to the healthy control
group, observed in the posterior putamen (p b 0.005). Although the
mean P.E. in the caudate of subjects with AD was lower than that of
healthy controls, this difference did not reach statistical signiﬁcance
(95% conﬁdence interval−45.7–8.1).
3.3. The diagnostic utility of resting state connectivity
In order to ascertain the diagnostic utility of resting state connectiv-
ity analyses, and represent basal ganglia activity as a whole, the mean
parameter estimates across the four regions of interest were coalesced
into a single component score using principal component analysis
(PCA)-based dimensionality reduction. The component accounted for
68.3% of the total variance in the data.
Table 1
Comparisons of demographic and anatomical characteristics.
Healthy controls (HC) Subjects with Alzheimer3s disease (AD) Subjects with Parkinson3s disease (PD) Group comparisons
Demographic characteristics
n 19 31 32 −
Age, years 60.6 (7.7) 74.5 (6.5) 62.1 (11.9) AD−HCa, AD−PDa
Gender, F:M 8:11 15:16 14:18 ns
Disease duration, months − − 25.0 (13.9) −
Mean LEDD, mg − − 332 (226) −
UPDRS III (OFF) − − 27.0 (12.6) −
MMSE 29.4 (1.4) 20.7 (5.7) 28.4 (1.6) AD−HCa, AD−PDa
Anatomical characteristics
Corrected total grey matter volume, cm3 705.2 (47.1) 640.6 (38.1) 697.5 (47.9) AD−HCa, AD−PDa
Corrected volume of the caudate, cm3 4.4 (0.6) 4.6 (0.5) 4.5 (0.4) ns
Corrected volume of the pallidum, cm3 2.3 (0.3) 2.2 (0.5) 2.3 (0.4) ns
Corrected volume of the putamen, cm3 6.0 (0.6) 5.2 (0.7) 5.9 (0.8) AD−HCa, AD−PDa
F, female; M, male; MMSE, Mini-Mental State Examination; ns, non-signiﬁcant.
a Post hoc test signiﬁcant at p b .0005.
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component score was signiﬁcantly lower in Parkinson3s disease than
that in healthy subjects and subjects with Alzheimer3s disease
(Fig. 4a). The mean component score did not correlate with diseaseFig. 2.Voxel-wise analysis conﬁned to the basal ganglia showing decreased connectivity in
PD patients compared to a) healthy controls; b) patients with Alzheimer3s disease; and
c) patients with Alzheimer3s disease and healthy controls, combined. Results show
signiﬁcantly reduced connectivity in PD in all regions of the basal ganglia. In image c,
voxels showing reduced connectivity make up 68.9%, 99.0% 98.3% and 99.7% of the total
volume of the caudate, pallidum, anterior putamen and the posterior putamen,
respectively.Images are displayed in radiological convention (right is left). Clusters are
thresholded at p N 0.05 after FWE correction.severity (UPDRS III motor score) or disease duration. The receiver oper-
ating characteristic (ROC) area under the curve (AUC)was 0.81 (95% C.I.
0.71–0.90), when comparing the PD group to the group including both
HC and AD (Fig. 4b). The mean component score was a better discrimi-
nator than when the individual mean parameter estimates from the
four regions of interest were used. The mean component score for PD
patients scanned in the clinically deﬁned “on-state” was signiﬁcantly
higher than those in the “off-state” (p b 0.0001). There was no statisti-
cally signiﬁcant difference between PD patients taking dopaminergic
medication, patients with Alzheimer3s disease and healthy controls
(p = 0.4).5. Discussion
Using resting state fMRI we have previously shown connectivity dif-
ferences in patients with PD relative to controls. Using a reﬁned meth-
odology, here we reproduce this ﬁnding and show that aberrant
connectivity within the basal ganglia network is not a widespread fea-
ture of neurodegeneration, being absent in AD. Moreover, by extracting
mean parameter estimates from a priori deﬁned regions of interest
within the basal ganglia, we have shown that resting-connectivity of
the basal ganglia may have a potential role as a diagnostic biomarker
for PD. Hence, by moving away from a single study-speciﬁc design
and by including disease controls, we contribute to the translational
pipeline for the development of reliable and clinically useful imaging
biomarkers.
In line with previous task based (Monchi et al., 2007; Wu et al.,
2010) and resting state studies (Hacker et al., 2012; Wu et al., 2012;
Szewczyk-Krolikowski et al., 2014a), we have comprehensively shown
reduced connectivity within the basal ganglia network in PD subjects,
including the caudate, putamen and pallidum, when compared to
healthy controls. Importantly, we have also shown that the reduction
in resting state connectivity is apparent in the PD group not only
when compared to a healthy aged population, but also to patients
with another diffuse neurodegenerative condition, in this case,
Alzheimer3s disease, which is typically associated with changes within
the default mode network (DMN) (Greicius et al., 2004). At face value,
thismay seem somewhat surprising given the evidence for basal ganglia
involvement in AD from pathophysiological (Ikonomovic et al., 2008)
and imaging studies (de Jong et al., 2008; Madsen et al., 2010). Indeed,
we have shown reduced total greymatter volume, aswell as the volume
of the putamen, in patients with AD, when compared to those with PD.
Despite this, dopamine and homovanillic acid levels seem not to be
altered in AD (Langlais et al., 1993), suggesting that overall function
is preserved. This may explain why there are no statistically sig-
niﬁcant differences in resting state connectivity between patient
with AD and healthy controls. Therefore, resting state connectivity
Fig. 3. Regions of interest analysis. Average of the mean P.E. extracted bilaterally from the
regions of interest, expressed as a proportion of the mean P.E. for that region in healthy
controls (mean± standard error of the mean). Results demonstrate signiﬁcantly reduced
P.E. in all regions in PD, compared to healthy controls and patients with Alzheimer3s dis-
ease. HC, healthy controls; AD, Alzheimer3s disease; PD, Parkinson3s disease; P.E., parame-
ter estimates; ant. Puta, anterior putamen; post. Puta, posterior putamen.
Table 2
Mean parameter estimates extracted from regions of interest within the basal ganglia.
Healthy controls (HC) Subjects with Alzheimer3s disease (AD) Subjects with Parkinson3s disease (PD) Group comparisons
Caudate 27.6 (15.6) 22.6 (12.0) 16.0 (7.0) AD−PDa, HC−PDa
Pallidum 17.0 (9.7) 17.2 (10.6) 10.0 (6.3) AD−PCb, HC−PDb
Anterior putamen 36.5 (14.4) 35.5 (14.4) 22.7 (7.4) AD−PDc, HC−PDc
Posterior putamen 21.8 (11.0) 19.6 (11.1) 10.0 (7.9) AD−PDa, HC−PDa
a Post hoc test signiﬁcant at p b .005.
b Post hoc test signiﬁcant at p b .05.
c Post hoc test signiﬁcant at p b .0005.
130 M. Rolinski et al. / NeuroImage: Clinical 8 (2015) 126–132seems to reﬂect basal ganglia function independently from non-speciﬁc
neurodegeneration.
As can be seen from the voxel-wise analyses (Fig. 2), the involve-
ment of the basal ganglia in PD is not uniform,with the caudate relative-
ly spared. The difference in mean PE3s is particularly striking between
the caudate and posterior putamen (Fig. 3). This is in agreement with
previous post-mortem (Goldstein et al., 2011; Kish et al., 1988; Wilson
et al., 1996) and radiotracer imaging (Morrish et al., 1998; Nurmi
et al., 2001) studies showing a heterogeneous pattern of basal ganglia
involvement in PD, with the greatest loss of dopaminergic function in
the posterior putamen, and caudate the least affected. Moreover, a re-
cent seed-based resting state connectivity study (Hacker et al., 2012)Fig. 4. The diagnostic utility of resting state connectivity. a) Mean component scores were calc
method by combining themean parameter estimates from each of the regions of interest. Resul
with Alzheimer3s disease and healthy controls. ***p b 0.0001. b) Individual component scores w
was 0.80 (95% C.I. 0.68–0.93), 0.81 (95% C.I. 0.71–0.92) and 0.81 (95% C.I. 0.71–0.90) for the
Alzheimer3s disease; PD, Parkinson3s disease; All, group comprised of healthy controls and patishowed a graded pattern of striatal functional connectivity with the
brainstem of patient with PD and healthy controls. The authors specu-
lated that this gradient represents the underlying susceptibility to dopa-
minergic dysfunction in PD.
When combined into a single component score using a data-driven
dimensionality reduction technique, reduced connectivity scoreswithin
the basal ganglia separated patients with PD from the other participants
with a diagnostic sensitivity of 81%, similar to the 85% diagnostic accu-
racy using the method previously described by our group (Szewczyk-
Krolikowski et al., 2014a). The method used herein may, however,
have a number of advantages. Firstly, parameter estimateswere extract-
ed fromwhole regions of interest selected a priori on the basis that they
are known to play a key role in the pathophysiology of Parkinson3s dis-
ease. This is in contrast to the previous method where parameter esti-
mates were extracted using a mask of voxels in the PD group that
showed reduced connectivity when compared to a healthy control
group. As this mask was created from a relatively small number of par-
ticipants, the results obtained using it may not be transferrable to other
patient groups and MRI scanners. Clearly, both methods of obtaining
measures of basal ganglia function must be validated on a completely
separate group of PD patients and healthy controls. Secondly, by focus-
sing on regions of interest, this method allows us to study the function
of individual constituents of the basal ganglia. The pattern of decreased
connectivity resembles that obtained using radiotracer imaging and has
the potential to further our understanding of the pathophysiology of
Parkinson3s disease.
Further testing of larger independent study groups is necessary to
validate our results. Moreover, in order to reduce imaging artefacts
and conceivable confounding effects on the basal ganglia network, the
generalisability of ourﬁndingsmayhave been limited by excluding sub-
jects with tremor-dominant disease. Whilst previous studies have not
found any difference in basal ganglia connectivity in patients with and
without tremor (Helmich et al., 2010), and tremor does not appear to
be correlated with basal ganglia dysfunction (Benamer et al., 2003;
Eidelberg et al., 1995; Isaias et al., 2007), further studies are necessary
to conﬁrm that the results of this study are transferrable to theulated using a data-driven principal component analysis-based dimensionality reduction
ts demonstrate a signiﬁcantly lower score in patients with PD, when compared to patients
ere used to generate receiver operating characteristic (ROC) curves. Area under the curve
PD vs HC, PD vs AD and PD vs All comparisons, respectively. HC, healthy controls; AD,
ents with Alzheimer3s disease.
131M. Rolinski et al. / NeuroImage: Clinical 8 (2015) 126–132tremor-dominant PD group. Lastly, the diagnostic accuracy of 81% using
the method described herein is less than the diagnostic accuracy of a
clinical assessment carried out by an experienced clinician (Hughes
et al., 1992). Current work is concentrating on the integration of multi-
ple brain networks to improve the sensitivity and speciﬁcity for PD.
Moreover, further studies are required to ascertain whether this meth-
od is sensitive enough to pick up basal ganglia dysfunction in prodromal
PD, for it to have a role as a potential imaging biomarker.
6. Conclusion
In conclusion, our results indicate that resting-state functional MRI
can be used to demonstrate the aberrant functional connectivity within
the basal ganglia of patients with early Parkinson3s disease. These
changes are not seen in Alzheimer3s disease, suggesting that they are
representative of true basal ganglia dysfunction, and not just general-
ised neurodegeneration. Although further validation is necessary,
extracting measures of functional connectivity from a priori regions of
interest within the basal ganglia shows promise as a diagnostic bio-
marker of PD.
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